Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP study

BACKGROUND: An objective of the phase 3 HELP Study was to investigate the effect of lanadelumab on health‐related quality of life (HRQoL) in patients with hereditary angioedema (HAE). METHODS: Patients with HAE‐1/2 received either lanadelumab 150 mg every 4 weeks (q4wks; n = 28), 300 mg q4wks (n = 2...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Allergy
Main Authors: Lumry, William R., Weller, Karsten, Magerl, Markus, Banerji, Aleena, Longhurst, Hilary J., Riedl, Marc A., Lewis, Hannah B., Lu, Peng, Devercelli, Giovanna, Jain, Gagan, Maurer, Marcus
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
ORIGINAL ARTICLES
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8247292/
https://ncbi.nlm.nih.gov/pubmed/33258114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/all.14680
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados